FDA approves EMBLAVEO for the treatment of adults with complicated intra-abdominal infections
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Subscribe To Our Newsletter & Stay Updated